Belite Bio (NASDAQ:BLTE – Get Free Report) posted its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.
Belite Bio Stock Down 3.0 %
Shares of BLTE stock opened at $67.44 on Monday. Belite Bio has a 12 month low of $31.01 and a 12 month high of $86.53. The company’s fifty day simple moving average is $58.40 and its 200-day simple moving average is $60.33. The firm has a market cap of $2.15 billion, a PE ratio of -60.76 and a beta of -1.54.
Analysts Set New Price Targets
Separately, Benchmark increased their price objective on shares of Belite Bio from $57.00 to $79.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Read More
- Five stocks we like better than Belite Bio
- Dividend Payout Ratio Calculator
- Adobe Earnings Are In: Should You Buy, Sell, or Hold Now?
- What is the Euro STOXX 50 Index?
- Maximize Your Dividends With These 3 High-Yield ETFs
- Investing In Automotive Stocks
- 3 Undervalued Stocks Poised for a Strong Comeback
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
